Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Heymach, John, Hai T. Tran, Andrew B. Nixon, Herbert Hurwitz, Jeffrey R. Infante, Robert C. Gagnon, Klaudia Steplewski, Ngocdiep T. Le, and Yuan Liu. “Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Scholars@Duke

Hurwitz, Herbert, Stephanie Cushman, Chen Jiang, Ivo Shterev, Michelle R. Mahoney, Donna Niedzwiecki, Robert J. Mayer, Alan Paul Venook, Kouros Owzar, and Andrew B. Nixon. “Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Scholars@Duke

Strickler, John H., Shannon McCall, Andrew B. Nixon, Herbert Pang, Christel Rushing, Christy Arrowood, Sherri Haley, Kellen Meadows, and Herbert Hurwitz. “Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Scholars@Duke

Knelson, Erik H., Angela L. Gaviglio, Alok K. Tewari, Michael B. Armstrong, Andrew B. Nixon, Mark D. Starr, Karthikeyan Mythreye, and Gerard C. Blobe. “Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma..” In Tumor Biology. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-5041.

Full Text

Liu, Yingmiao, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, and Andrew B. Nixon. “Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab..” Cancer Med 2, no. 2 (April 2013): 234–42. https://doi.org/10.1002/cam4.71.

PMID
23634291
Full Text

Jia, Jingquan, Alex Starodub, Ian Cushman, Yingmiao Liu, Deborah J. Marshall, Herbert I. Hurwitz, and Andrew B. Nixon. “Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer..” Anticancer Drugs 24, no. 3 (March 2013): 237–50. https://doi.org/10.1097/CAD.0b013e32835d29fd.

PMID
23275294
Full Text

Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas..” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.

PMID
23485624
Full Text

Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors..” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.

PMID
22744359
Full Text

Jia, Jingquan, Haiyan Li, Andrew Dellinger, Herbert Pang, Karen Bullock Russell, Herbert Hurwitz, and Andrew B. Nixon. “Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Scholars@Duke

Liu, Yingmiao, Mark Starr, John C. Brady, Herbert Pang, Andrew Dellinger, Bryan R. Leigh, Charles P. Theuer, Herbert Hurwitz, and Andrew B. Nixon. “Modulation of angiogenic biomarkers in patients receiving high-dose TRC105.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Scholars@Duke

Pages